Global X Autonomous & Electric Vehicles vs IDEXX Laboratories, Inc. — how do they compare? Global X Autonomous & Electric Vehicles trades at $32.79 (market cap $356.37M), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 113.4× Global X Autonomous & Electric Vehicles's market cap, and Global X Autonomous & Electric Vehicles is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Autonomous & Electric Vehicles for 40 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| DRIV | IDXX | |
|---|---|---|
Market Cap | $356.37M | $40.43B |
Volume | 22,397 | 692,164 |
Sector | Sector/Thematic | Health |
52-Week High | $42.53 | $766.68 |
52-Week Low | $27.58 | $504.70 |
Typical Hold Time | 40 Days | 46 Days |
Enterprise Value | — | $41.32B |
Signals from Pluang's Aura AI — not financial advice
DRIV trades at $32.79, down 1.72% today amid mixed technical signals. The stock shows a bullish overall technical signal but bearish moving averages, with neutral oscillators suggesting consolidation. Recent automotive sector news highlights hybrid vehicle momentum and China's EV ambitions, potentially impacting this automotive-focused investment.
Investment outlook remains cautious pending fundamental data verification. Key opportunities include exposure to automotive innovation trends, while risks involve sector volatility and reliance on unverified financial metrics. The technical setup suggests near-term consolidation around current levels.
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
Trailing returns across standard periods
DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.
Read more on DRIV →Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →